The Hyderabad-based firm, Aurobindo Pharma has reported consolidated net profit of Rs 91.81 crore during the third quarter ended December 2012 on account of lower foreign exchange loss, as against a net loss of Rs 28.54 crore in the corresponding period of last year. The company management declared interim dividend of 100 percent.
Mr N Govindarajan, managing director, Aurobindo Pharma, said, "We continue to see traction on our performance both in sales and earnings on year-on-year basis on account of improved business mix in formulations from new product approvals and launches in the US market. During the quarter, US FDA cleared Unit-4 (general liquid injectable) after their first inspection and Unit-12 (SSP oral and injectable) on re-inspection and started approving products from these facilities. These will pave the way for consolidating injectable formulations business."